Volition Announces Mayo Clinic Study Demonstrates Nu.Q® Concentrations are Elevated in Trauma Patients
PR Newswire —
Peer Reviewed Clinical Study for Nu.Q® Biomarkers Published in Shock Journal HENDERSON, Nev., March 30, 2026 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, announces the publication of a new clinical manuscript demonstrating...